Osobennosti vybora peroral'noy gormonal'noy kontratseptsii

作者: Yaglov VV¹
隶属关系:
1. ФГБУ Научный центр экспертизы средств медицинского применения Минздравсоцразвития РФ
期: 卷 13, 编号 5 (2011)
页面: 49-52
栏目: Articles
URL: https://journal-vniispk.ru/2079-5831/article/view/33239
ID: 33239

如何引用文章

全文:

ФГБУ Научный центр экспертизы средств медицинского применения Минздравсоцразвития РФ

Прилепская В.Н. Руководство по контрацепции. М.: МЕДпресс-информ, 2010.
Критерии приемлемости использования методов контрацепции. ВОЗ, 2009.
WHO. Medical eligibility criteria for contraceptive use. 4th edition. Geneva 2009.
Rice CF, Killick SR, Dieben T, Coelingh Bennink H. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Hum Reprod 1999; 14: 982-5.
Winkler UH, Howie H, Buehler K et al. A randomized controlled double-blind study of the effects on hemostasis of two progestogen-only pills containing 75 mcg desogestrel and 30 mcg levonorgestrel. Contraception 1998; 57: 385-92.
Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on lipid metabolism. Contraception 2001; 64 (5): 295-300.
Kivelae A, Ruuskanen M, Aegren U, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 mcg/day) or levonorgestrel (30 mcg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001; 6: 71-7.

附件文件

动作

1. JATS XML